Product category:
Ultrasound equipment and ultrasonic spectroscopy
News Release from: Akubio | Subject: Rapid 4 system
Edited by the Laboratorytalk Editorial
Team on 15 February 2007
System to play big role in therapeutic
projects
With RAP technology, protein interactions are specifically measured in crude and complex mixtures thereby eliminating expensive and time-consuming purification procedures
Akubio reports that it has installed a Rapid 4 system at UCB As an early access partner UCB has assisted in the development of the new analytical instrument which measures molecular interactions - a vital process in the research and discovery of new biological drugs such as proteins and antibodies
This article was originally published on Laboratorytalk on 24 Jul 2003 at 8.00am (UK)
Related stories
Acoustic technology granted US patent
Revolutionary system can sensitively, rapidly and economically detect analytes in complex fluids such as serum without the need for radio-, enzymatic or fluorescent labels
Acoustic analysis of biomolecular interactions
Based on resonant acoustic profiling (Rap), Rapid4 enables real-time label-free measurement and analysis of biomolecular interactions with the highest level of accuracy reproducibility and sensitivity
By basing its innovative technology on quartz resonators similar to those used in wrist watches, Akubio is able to provide pharmaceutical researchers with precise information on how well proteins interact with each other and with drug candidates by providing real time data on specificity, binding rates and binding affinity, with the potential to design better drugs.
Traditional methods of measuring protein-protein interactions rely either on the addition of radioactive labels, which is time consuming and can affect interactions between molecules, or optical sensors, which are complex and prone to interference.
With RAP technology, protein interactions are specifically measured in crude and complex mixtures thereby eliminating expensive and time-consuming purification procedures.
Alastair Lawson, director of antibody biology at UCB, said: "At UCB we are always looking for innovative ways to strengthen our antibody technology.
"We saw Akubio's RAP technology as a potentially powerful tool and have provided significant input to the development of the Rapid 4.
"The Rapid 4 product will be an important tool for advancing our therapeutic projects".
Andrew Mackintosh, chief executive officer of Akubio, commented: "Our collaboration with UCB, a global leader in the field of antibody engineering, has been an important contribution to the commercialisation of RAP technology.
"We are delighted to announce the installation of a Rapid 4 instrument in their facility and look forward to continuing our close relationship in the future.".
• Akubio: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
